-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] On August 17, the China Securities Regulatory Commission approved the registration application of 4 companies for their initial public offering and listing on the Growth Enterprise Market
.
Three of them are pharmaceutical companies, including Enwei Pharmaceutical Co.
, Ltd.
, Shanghai Hongbo Zhiyuan Pharmaceutical Co.
, Ltd.
, and Shenzhen Meichuangyi Medical Technology Co.
,
Ltd.
Enwei Pharmaceutical plans to raise 700 million yuan to enhance the competitiveness of its main business Enwei Pharmaceutical was established in May 2005, mainly engaged in the research and development, production and sales of Chinese patent medicines and chemical drugs, focusing on gynecological products, pediatric drugs, respiratory system drugs, etc.
field
.
The company currently holds dozens of drug approval numbers, covering eight fields including gynecology, pediatrics, respiratory, tonic, oral cavity, cardiovascular and cerebrovascular, hepatobiliary, and dermatology.
, 17 varieties such as Shanmai Jianpi Oral Liquid, Jinzhijie Gum Gargle,
etc.
According to the prospectus, Enwei Pharmaceutical will publicly issue no more than 17.
54 million shares this time, and all the funds raised will be used for projects related to the company's main business, including the reconstruction and expansion project of Sichuan Enwei Pharmaceutical and the construction project of Qamdo Headquarters
.
Enwei Pharmaceutical stated that it will make full use of the opportunity of this public offering and listing to continuously enhance the company's industry position and competitive advantage
.
Meihao Medical intends to raise 1 billion yuan to build the key equipment for the diagnosis and treatment of respiratory system diseases in Meiyi Chuangyi.
Shenzhen Meiyi Chuangyi Medical Technology Co.
,
Ltd.
According to the data, Good Medical is mainly engaged in the design, development, manufacture and sales of precision components and products for medical devices.
Its main products include home ventilators, cochlear implant components, precision molds and automation equipment
.
On April 14, 2022, the GEM Listing Committee announced that Meihao Medical met the issuance conditions, listing conditions and information disclosure requirements
.
On August 17, the China Securities Regulatory Commission approved the company's GEM IPO registration
.
According to the prospectus, Meihao Medical is expected to issue no less than 44.
27 million shares to raise 1 billion yuan, which will be used to build the “R&D and production project of Meiyi Chuangyi’s key equipment for the diagnosis and treatment of respiratory diseases and a cloud platform for respiratory health big data management”
.
The prospectus shows that home ventilator components are the main source of income for Meihao Medical, but it is this core business that is highly dependent on orders from a single overseas customer
.
Hongbo Pharmaceutical plans to raise funds to invest in new drug research and development base Hongbo Pharmaceutical is a one-stop comprehensive service provider for new drug development and commercial production, dedicated to drug discovery, pharmaceutical process research and development, and commercial production of API intermediates
.
Based on the key links in the new drug research and development industry chain, the company builds a comprehensive technical service platform covering drug discovery, process research and development, as well as a commercial production platform for the production of new drug key intermediates and independent products
.
It is reported that on April 21, at the 21st issuance review meeting of the GEM Listing Committee in 2022, Hongbo Medicine passed the meeting with conditions
.
Hongbo Pharma plans to raise 477 million yuan for two projects, namely, the construction of preclinical new drug research and development bases and the replenishment of working capital
.
It is planned to invest 387 million yuan in the construction of new drug research and development bases
.
On August 17, the China Securities Regulatory Commission approved the company's GEM IPO registration
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Three of them are pharmaceutical companies, including Enwei Pharmaceutical Co.
, Ltd.
, Shanghai Hongbo Zhiyuan Pharmaceutical Co.
, Ltd.
, and Shenzhen Meichuangyi Medical Technology Co.
,
Ltd.
Enwei Pharmaceutical plans to raise 700 million yuan to enhance the competitiveness of its main business Enwei Pharmaceutical was established in May 2005, mainly engaged in the research and development, production and sales of Chinese patent medicines and chemical drugs, focusing on gynecological products, pediatric drugs, respiratory system drugs, etc.
field
.
The company currently holds dozens of drug approval numbers, covering eight fields including gynecology, pediatrics, respiratory, tonic, oral cavity, cardiovascular and cerebrovascular, hepatobiliary, and dermatology.
, 17 varieties such as Shanmai Jianpi Oral Liquid, Jinzhijie Gum Gargle,
etc.
According to the prospectus, Enwei Pharmaceutical will publicly issue no more than 17.
54 million shares this time, and all the funds raised will be used for projects related to the company's main business, including the reconstruction and expansion project of Sichuan Enwei Pharmaceutical and the construction project of Qamdo Headquarters
.
Enwei Pharmaceutical stated that it will make full use of the opportunity of this public offering and listing to continuously enhance the company's industry position and competitive advantage
.
Meihao Medical intends to raise 1 billion yuan to build the key equipment for the diagnosis and treatment of respiratory system diseases in Meiyi Chuangyi.
Shenzhen Meiyi Chuangyi Medical Technology Co.
,
Ltd.
According to the data, Good Medical is mainly engaged in the design, development, manufacture and sales of precision components and products for medical devices.
Its main products include home ventilators, cochlear implant components, precision molds and automation equipment
.
On April 14, 2022, the GEM Listing Committee announced that Meihao Medical met the issuance conditions, listing conditions and information disclosure requirements
.
On August 17, the China Securities Regulatory Commission approved the company's GEM IPO registration
.
According to the prospectus, Meihao Medical is expected to issue no less than 44.
27 million shares to raise 1 billion yuan, which will be used to build the “R&D and production project of Meiyi Chuangyi’s key equipment for the diagnosis and treatment of respiratory diseases and a cloud platform for respiratory health big data management”
.
The prospectus shows that home ventilator components are the main source of income for Meihao Medical, but it is this core business that is highly dependent on orders from a single overseas customer
.
Hongbo Pharmaceutical plans to raise funds to invest in new drug research and development base Hongbo Pharmaceutical is a one-stop comprehensive service provider for new drug development and commercial production, dedicated to drug discovery, pharmaceutical process research and development, and commercial production of API intermediates
.
Based on the key links in the new drug research and development industry chain, the company builds a comprehensive technical service platform covering drug discovery, process research and development, as well as a commercial production platform for the production of new drug key intermediates and independent products
.
It is reported that on April 21, at the 21st issuance review meeting of the GEM Listing Committee in 2022, Hongbo Medicine passed the meeting with conditions
.
Hongbo Pharma plans to raise 477 million yuan for two projects, namely, the construction of preclinical new drug research and development bases and the replenishment of working capital
.
It is planned to invest 387 million yuan in the construction of new drug research and development bases
.
On August 17, the China Securities Regulatory Commission approved the company's GEM IPO registration
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
![9-[3-Chloro-5-(phenanthren-9-yl)phenyl]phenanthrene / 1369431-34-4](https://file.echemi.com/fileManage/upload/goodpicture/20241028/9-3-chloro-5-phenanthren-9-ylphenylphenanthrene-1369431-34-4_b20241028151130118.jpg)
